Journal
EPIGENOMICS
Volume 12, Issue 16, Pages 1457-1476Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2020-0186
Keywords
cancer immunotherapy; epigenetics; EZH2; immune editing
Categories
Funding
- Higher Education Innovation Fund (HEIF-UK)
- Canadian Foundation for Translational Immunology
- CIHR [141635, 144159, 153081]
- TFRI program project [1062]
- MITACS [IT14958]
- National Cancer Institute [P50CA097186]
Ask authors/readers for more resources
Immunotherapies are revolutionizing the clinical management of a wide range of cancers. However, intrinsic or acquired unresponsiveness to immunotherapies does occur due to the dynamic cancer immunoediting which ultimately leads to immune escape. The evolutionarily conserved histone modifier enhancer of zeste 2 (EZH2) is aberrantly overexpressed in a number of human cancers. Accumulating studies indicate that EZH2 is a main driver of cancer cells' immunoediting and mediate immune escape through downregulating immune recognition and activation, upregulating immune checkpoints and creating an immunosuppressive tumor microenvironment. In this review, we overviewed the roles of EZH2 in cancer immunoediting, the preclinical and clinical studies of current pharmacologic EZH2 inhibitors and the prospects for EZH2 inhibitor and immunotherapy combination for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available